文献速递其他结缔组织病

细化原发性干燥综合征相关肌炎:ASSESS前瞻性队列数据

Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

该多中心前瞻性ASSESS队列纳入395例病程≥60个月的原发性干燥综合征(pSS)患者,按2017 EULAR/ACR肌炎标准筛查,肌炎确诊率为1.0%(95%CI:0.40,2.6)。确诊肌炎者病程为无肌炎者的3倍,其中2例符合散发性包涵体肌炎(IBM)且对多线治疗无肌肉改善,另2例为「纯」pSS肌炎且激素联合甲氨蝶呤(MTX)可达缓解。

要点

  • pSS患者肌炎确诊率约1%,疑似者常见关节及周围神经受累且患者报告评分更高。
  • 确诊肌炎者病程显著更长,治疗抵抗时需考虑散发性IBM。
  • 无肌炎亚型特征的「纯」pSS肌炎对激素联合MTX治疗有效。

核心结论

  • 肌炎在pSS患者中常被怀疑但确诊率约1%,散发性IBM应视为该病的晚期并发症。
  • 对治疗抵抗的pSS肌炎患者应考虑散发性IBM,而「纯」pSS肌炎对激素联合MTX有效。

研究设计与样本

  • 多中心前瞻性ASSESS队列纳入395例随访≥60个月的pSS患者,按2017 EULAR/ACR肌炎标准筛查。

主要发现

  • 入组前及5年随访中,38例pSS患者被怀疑肌炎,仅4例确诊,确诊率1.0%(95%CI:0.40,2.6)。
  • 疑似但未确诊肌炎者较其他人患者报告评分更高,关节及周围神经受累更频繁。
  • 确诊肌炎者病程为无肌炎者的3倍。
  • 4例确诊肌炎患者中2例符合散发性IBM标准,接受≥3线治疗仍无肌肉改善。
  • 另2例无肌炎亚型特征,提示「纯」pSS肌炎,激素联合MTX有效达缓解。

关键数值与推荐

  • 肌炎诊断采用2017 EULAR/ACR标准。
  • pSS肌炎确诊率1.0%(95%CI:0.40,2.6)。
  • 散发性IBM判定依据:符合标准且接受≥3线治疗无肌肉改善。

临床怎么用

  • 对pSS患者出现疑似肌炎表现应行2017 EULAR/ACR标准评估以明确诊断。
  • 确诊肌炎且对多线治疗抵抗时,应考虑散发性IBM并重新评估治疗策略。
  • 无肌炎亚型特征的「纯」pSS肌炎可选用激素联合MTX治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To refine the prevalence, characteristics and response to treatment of myositis in primary SS (pSS). METHODS: The multicentre prospective Assessment of Systemic Signs and Evolution in Sjögren's Syndrome (ASSESS) cohort of 395 pSS patients with ≥60 months' follow-up was screened by the 2017 EULAR/ACR criteria for myositis. Extra-muscular complications, disease activity and patient-reported scores were analysed. RESULTS: Before enrolment and during the 5-year follow-up, myositis was suspected in 38 pSS patients and confirmed in 4 [1.0% (95% CI: 0.40, 2.6)]. Patients with suspected but not confirmed myositis had higher patient-reported scores and more frequent articular and peripheral nervous involvement than others. By contrast, disease duration in patients with confirmed myositis was 3-fold longer than without myositis. Two of the four myositis patients fulfilled criteria for sporadic IBM. Despite receiving three or more lines of treatment, they showed no muscle improvement, which further supported the sporadic IBM diagnosis. The two other patients did not feature characteristics of a myositis subtype, which suggested 'pure' pSS myositis. Steroids plus MTX was then efficient in achieving remission. CONCLUSIONS: Myositis, frequently suspected, occurs in 1% of pSS patients. Especially when there is resistance to treatment, sporadic IBM should be considered and might be regarded as a late complication of this disease.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Felten R, Giannini M, Nespola B, et al. Refining myositis associated with primary Sjögren's syndrome: data from the prospective cohort ASSESS. Rheumatology (Oxford). 2021. PMID: 32780813. doi:10.1093/rheumatology/keaa257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。